Drug intelligence / Profile preview

TKD-006

Development stage: Preclinical
Lead developer: Therakind
Modality: Small Molecules
Administration: Intranasal

Overview

TKD-006 is a small molecule therapeutic candidate being developed by Therakind for the symptomatic relief of neurodegenerative diseases. The drug is designed for intranasal administration, potentially utilizing Therakind's proprietary delivery technologies to improve drug uptake and patient compliance. As of the current development stage, the specific active ingredient and biological target of TKD-006 have not been disclosed by the sponsor.

Beyond the preview

Go deeper on TKD-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TKD-006.

Explore the full profile